VELUSETRAG
Velusetrag is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against 5-hydroxytryptamine receptor 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
No data
Commercial
No data
Clinical
No data
Drug
General
| Drug common name | VELUSETRAG |
| INN | velusetrag |
| Description | Velusetrag (INN, USAN; previously known as TD-5108) is an experimental drug candidate for the treatment of gastric neuromuscular disorders including gastroparesis, and lower gastrointestinal motility disorders including chronic idiopathic constipation and irritable bowel syndrome. It is a potent, selective, high efficacy 5-HT4 receptor serotonin agonist being developed by Theravance Biopharma and Alfa Wassermann. Velusetrag demonstrates less selectivity for other serotonin receptors, such as 5-HT2 and 5-HT3, to earlier generation 5-HT agonists like cisapride and tegaserod.
|
| Classification | Small molecule |
| Drug class | serotonin 5-HT receptor agonists, not principally 5-HT2 |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)n1c(=O)c(C(=O)N[C@@H]2C[C@@H]3CC[C@H](C2)N3C[C@@H](O)CN(C)S(C)(=O)=O)cc2ccccc21 |
Identifiers
| PDB | — |
| CAS-ID | 866933-46-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2087337 |
| ChEBI ID | — |
| PubChem CID | 53297466 |
| DrugBank | — |
| UNII ID | J4VNV64ARB (ChemIDplus, GSRS) |
Target
Agency Approved
HTR4
HTR4
Alternate
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use